Integration of nanotechnology in triple negative breast cancer research: a bibliometric and emerging trends analysis
The paper provides a bibliometric analysis of the integration of nanotechnology in triple‑negative breast cancer research from 2013 to 2025.
This review presents a bibliometric analysis of the literature on nanotechnology in triple‑negative breast cancer (TNBC) from 2013 to 2025, highlighting annual growth, leading countries and institutions, key authors, journal impact, and emerging research themes such as ferroptosis, immunotherapy and RNA nanotechnology. The study calls for further research into ferroptosis‑based therapies, nano‑enabled immunotherapy and multimodal nanotheranostics to advance clinical translation in TNBC.
It identifies growth trends, leading contributors, and emerging research directions, informing future studies and funding priorities for TNBC nanotechnology.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC